Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $94.57

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have received an average rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $94.57.

LMAT has been the topic of a number of recent analyst reports. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price on the stock. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Lake Street Capital started coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a "buy" rating and a $105.00 price objective for the company. Oppenheimer reissued an "outperform" rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 20th.

LeMaitre Vascular Price Performance

LMAT traded up $0.37 during trading hours on Thursday, reaching $105.80. 86,898 shares of the stock traded hands, compared to its average volume of 124,239. LeMaitre Vascular has a fifty-two week low of $51.70 and a fifty-two week high of $109.58. The company has a market cap of $2.38 billion, a price-to-earnings ratio of 57.81, a PEG ratio of 2.62 and a beta of 0.89. The firm's fifty day simple moving average is $94.86 and its two-hundred day simple moving average is $87.55.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period last year, the firm earned $0.33 earnings per share. The company's revenue was up 15.6% on a year-over-year basis. On average, research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.60%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular's payout ratio is currently 34.97%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the company's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.79% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds and other institutional investors have recently modified their holdings of the company. Driehaus Capital Management LLC grew its holdings in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock worth $21,740,000 after acquiring an additional 90,573 shares during the period. F M Investments LLC acquired a new stake in LeMaitre Vascular during the second quarter valued at approximately $7,443,000. DF Dent & Co. Inc. grew its position in LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier's stock worth $24,037,000 after buying an additional 53,797 shares during the last quarter. Nicholas Investment Partners LP bought a new position in shares of LeMaitre Vascular in the second quarter valued at $3,900,000. Finally, Janus Henderson Group PLC lifted its position in shares of LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier's stock valued at $3,697,000 after acquiring an additional 47,218 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.